Roland Goette
Known title: EVP and President, EMEACIK: 0001708067
Associated companies
Transaction History
| BDX | ▼ Sell | Open Market | 2,438 | $441K | 8/11/2026 | View on chart |
| BDX | ▲ Buy | Grant | 1,906 | $0 | 11/26/2025 | View on chart |
| BDX | ▲ Buy | Grant | 1,237 | $0 | 11/26/2025 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 138 | $0 | 11/26/2025 | View on chart |
| BDX | ▼ Sell | Open Market | 638 | $140K | 12/9/2024 | View on chart |
| BDX | ▲ Buy | Option Exercise | 6,995 | $1.0M | 12/6/2024 | View on chart |
| BDX | ▲ Buy | Option Exercise | 6,339 | $1.1M | 12/6/2024 | View on chart |
| BDX | ▼ Sell | Open Market | 4,483 | $991K | 12/6/2024 | View on chart |
| BDX | ▼ Sell | Other | 9,490 | $2.1M | 12/6/2024 | View on chart |
| BDX | ▲ Buy | Grant | 944 | $0 | 11/26/2024 | View on chart |
| BDX | ▲ Buy | Grant | 2,161 | $0 | 11/26/2024 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 196 | $0 | 11/26/2024 | View on chart |
| BDX | ▲ Buy | Option Exercise | 5,295 | $702K | 8/14/2024 | View on chart |
| BDX | ▼ Sell | Other | 4,018 | $941K | 8/14/2024 | View on chart |
| BDX | ▼ Sell | Open Market | 800 | $188K | 5/15/2024 | View on chart |
| BDX | ▼ Sell | Open Market | 1,400 | $332K | 5/15/2024 | View on chart |
| BDX | ▼ Sell | Open Market | 1,100 | $261K | 5/15/2024 | View on chart |
| BDX | ▼ Sell | Open Market | 1,700 | $402K | 5/13/2024 | View on chart |
| BDX | ▼ Sell | Open Market | 1,572 | $373K | 5/13/2024 | View on chart |
| BDX | ▼ Sell | Open Market | 28 | $7K | 5/13/2024 | View on chart |
| BDX | ▲ Buy | Grant | 582 | $0 | 11/26/2023 | View on chart |
| BDX | ▲ Buy | Grant | 2,608 | $0 | 11/26/2023 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 213 | $0 | 11/26/2023 | View on chart |
| BDX | ▲ Buy | Option Exercise | 3,544 | $380K | 11/16/2023 | View on chart |
| BDX | ▼ Sell | Other | 1,751 | $412K | 11/16/2023 | View on chart |
| BDX | ▲ Buy | Grant | 636 | $0 | 11/26/2022 | View on chart |
| BDX | ▲ Buy | Grant | 1,183 | $0 | 11/26/2022 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 99 | $0 | 11/26/2022 | View on chart |
| BDX | ▲ Buy | Option Exercise | 4,617 | $346K | 11/16/2022 | View on chart |
| BDX | ▼ Sell | Other | 2,996 | $665K | 11/16/2022 | View on chart |
| BDX | ▲ Buy | Grant | 312 | $0 | 11/26/2021 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 31 | $0 | 11/26/2021 | View on chart |
| BDX | ▲ Buy | Grant | 625 | $0 | 11/26/2021 | View on chart |
| BDX | ▲ Buy | Option Exercise | 3,055 | $220K | 11/16/2021 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 1,914 | $467K | 11/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%
The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.